MindRank raised $52 million in a Series B to advance MDR-001, its Phase III oral GLP-1 receptor agonist candidate in China. The company plans to scale its Molecule Arts Platform (MAP) and fund development activities through key trial milestones, targeting expansion of an oral weight-loss option. MindRank said MDR-001 entered Phase III (NCT07110766) after four and a half years of development, and it has secured multiple additional IND clearances across China and the U.S. The company positioned the program as a validation of its AI-first discovery engine. The financing underscores continued investor interest in oral alternatives to injectable GLP-1 therapies, where regulators have recently approved pill formulations in the U.S. MindRank’s stated use of proceeds centers on execution risk in the ongoing Phase III program and further preclinical candidate selection.